drugset
drugset / Trial / NCT00231621

A Study on Efficacy and Safety of Topiramate in Treatment of Obese Subjects With Dyslipidemia

NCT00231621 ↗

Phase 3 Terminated 179 enrolled Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to compare the efficacy and safety of daily topiramate versus placebo for the treatment of obese subjects with dyslipidemia.

Timeline

Start
2001-05
Primary completion
—
Completion
2002-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Topiramate Small molecule 96 mg Oral
Subject Topiramate Small molecule 192 mg Oral

Indications

hyperlipidemia hypertriglyceridemia obesity disorder